Doseology SciencesDOSEF -16.16%33 PB Ratio is 1.12 as of Jun. 24, 2026, which is 13% above its 10-year median of 0.99. GuruFocus rates DOSEF with a GF Score™ of 33/100 and a GF Value™ of $0.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, Doseology Sciences ranks better than 85.4% on this metric.
The historical rank and industry rank for Doseology Sciences's PB Ratio or its related term are showing as below:
DOSEF'
s PB Ratio Range Over the Past 10 Years
Min: 0.27 Med: 0.99 Max: 10.67
Current: 2.01
During the past 6 years, Doseology Sciences's highest PB Ratio was 10.67. The lowest was 0.27. And the median was 0.99.
DOSEF's PB Ratio is ranked better than 85.4% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs DOSEF: 2.01
During the past 12 months, Doseology Sciences's average Book Value Per Share Growth Rate was -26.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -37.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -15.10% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Doseology Sciences was 6.60% per year. The lowest was -37.50% per year. And the median was -28.20% per year.
Back to Basics: PB Ratio
Doseology Sciences (OTCPK:DOSEF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Doseology Sciences PB Ratio Related Terms
Doseology Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Doseology Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Doseology Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doseology Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Doseology Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Doseology Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Doseology Sciences (DOSEF) has a PB Ratio of 1.12 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Doseology Sciences and its competitors. This is 13% above median its historical median of 0.99. Over the past decade, Doseology Sciences' PB Ratio has ranged from 0.27 to 10.67. According to the industry distribution chart, Doseology Sciences ranks #180 out of 1233 companies in the Biotechnology industry, placing it in the top 14.6%.
Is Doseology Sciences' PB Ratio too high?
Doseology Sciences' current PB Ratio of 1.12 is 13% above median its 10-year median of 0.99. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 10.67. The Biotechnology industry median PB Ratio is 2.83. Doseology Sciences' value of 1.12 is 60.4% below this industry median. Based on the distribution chart, Doseology Sciences ranks #180 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Doseology Sciences has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Doseology Sciences' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Doseology Sciences ranks #180 out of 1233 companies for PB Ratio. This places Doseology Sciences in the top 15% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.83. Doseology Sciences' value of 1.12 is 60.4% below this benchmark. Historically, Doseology Sciences' own PB Ratio has ranged from 0.27 to 10.67 over the past decade. While the company's 10-year median is 0.99 vs. the industry median of 2.83, Doseology Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Doseology Sciences's current PB Ratio of 1.12 is 60.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Doseology Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doseology Sciences's current PB Ratio is 1.12, which is 13% above median its own 10-year median of 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doseology Sciences stock overvalued right now?
Based on GuruFocus' analysis, Doseology Sciences (DOSEF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.29, compared to a current price of $0.11 — trading 61.3% below its estimated fair value. The current PB Ratio is 1.12, which is 13% above median its 10-year median of 0.99 and 60.4% below the Biotechnology industry median of 2.83. Doseology Sciences' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Doseology Sciences (DOSEF), the current PB Ratio is 1.12 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doseology Sciences (DOSEF) Overvalued in 2026?
Based on GuruFocus' analysis, Doseology Sciences stock appears to be undervalued.
The current stock price of $0.11 is trading 61.3% below its estimated GF Value™ of $0.29.
GuruFocus considers Doseology Sciences to be Possible Value Trap.
Key valuation signals for DOSEF:
PB Ratio: 1.12 (13% above median its 10-year median of 0.99)
GF Value™: $0.29 vs. price of $0.11 (61.3% below fair value)
Industry Position: 60.4% below the Biotechnology median (#180 of 1233)
No single metric tells the full story. See the DOSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. It offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.
33GF Score
Get the complete analysis for DOSEF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOSEF has been successfully added to your 
